ReviewMolecular biomedicine2026
MFSD2A in health and disease: lysolipid transport, barrier physiology, and translational boundaries.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Major facilitator superfamily domain-containing protein 2A (MFSD2A) is a sodium-dependent lysolipid transporter that delivers lysophosphatidylcholine-bound fatty acids, particularly docosahexaenoic acid, across specialized cellular interfaces. This Review synthesizes structural, biochemical, physiological, genetic, and disease evidence through an evidence-weighted transport-to-barrier-to-disease framework. We first examine substrate recognition, sodium coupling, conformational transport, and the membrane lipid consequences of lysophosphatidylcholine uptake. We then detail the best-established physiological setting, central nervous system endothelium, where MFSD2A supports brain docosahexaenoic acid accretion, blood-brain barrier maturation, and suppression of caveolae-mediated transcytosis. Evidence from the retina, placenta, lung, kidney, epidermis, and immune cells is compared to define tissue-specific deployment rather than a universal downstream pathway. Rare biallelic variants and experimental loss-of-function models provide the strongest disease evidence, linking impaired lysolipid transport to deficient brain lipid supply, microcephaly, and neurodevelopmental abnormalities. Acquired vascular injury studies associate MFSD2A dysregulation with barrier leakage, whereas proposed roles in cancer, immunotherapy response, and patient stratification remain context-dependent and largely associative. We also assess translational concepts, including barrier stabilization, central nervous system drug delivery, biomarker development, and structure-guided modulation, emphasizing unresolved requirements for selectivity, reversibility, safety, and prospective validation. By distinguishing transporter-intrinsic mechanisms from secondary lipid remodeling and disease correlations, this Review clarifies which functions are established, which are tissue restricted, and which remain hypotheses. This framework identifies experimental priorities for linking MFSD2A activity to clinically informative phenotypes without extrapolating beyond current evidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.